- Details
-
Category: Bio Pharmaceuticals
Zydus is setting up a new unit in its special economic zone (SEZ) near Ahmedabad with an investment of Rs.1000 million. It will manufacture of transdermal patches and various injectables. Few years back, the company had launched country’s first indigenously-manufactured diclofenac transdermal patch for pain relief and it is increasingly accepted in US. NuPatch contains 100 mg of diclofenac, a painkiller. Instead of the thrice-a-day dosage as in the case of the oral dosage form, NuPatch needs to be applied just once in a day and provides extended pain relief. The overseas market for transdermal patches is estimated at USD 5 billion as compared to the Indian market ,which is pegged at around Rs 1000 million.
